Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.28 +9.0%	$0.27	$0.20 ▼ $1.48	$67.06M	2.18	1.63 million shs	906,181 shs
ALLO Allogene Therapeutics	$1.21 +0.8%	$1.24	$0.86 ▼ $3.78	$262.48M	0.31	3.28 million shs	9.59 million shs
INZY Inozyme Pharma	$4.00	$3.39	$0.72 ▼ $6.24	$258.25M	2.27	932,836 shs	N/A
TNXP Tonix Pharmaceuticals	$38.36 +7.9%	$31.67	$6.76 ▼ $130.00	$261.62M	2.05	959,394 shs	747,728 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+9.01%	+13.78%	-2.09%	+28.28%	-77.02%
ALLO Allogene Therapeutics	+0.83%	+0.83%	-14.18%	-11.68%	-47.39%
INZY Inozyme Pharma	0.00%	0.00%	+0.50%	+354.18%	-13.04%
TNXP Tonix Pharmaceuticals	+7.87%	+9.07%	-2.14%	+121.73%	-36.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.1267 of 5 stars	3.1	5.0	1.3	0.8	0.0
ALLO Allogene Therapeutics	2.9911 of 5 stars	4.5	1.0	0.6	3.3	0.6
INZY Inozyme Pharma	3.3842 of 5 stars	4.2	4.0	1.8	2.5	0.0
TNXP Tonix Pharmaceuticals	2.5211 of 5 stars	3.5	2.0	0.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	390.09% Upside
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	597.89% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,425.03% Upside

Current Analyst Ratings Breakdown

Latest ADAP, TNXP, ALLO, and INZY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.41	N/A	N/A	$0.05 per share	5.52
ALLO Allogene Therapeutics	$20K	13,233.17	N/A	N/A	$2.01 per share	0.60
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
TNXP Tonix Pharmaceuticals	$10.09M	27.98	N/A	N/A	$31.82 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)

Latest ADAP, TNXP, ALLO, and INZY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	N/A	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
ALLO Allogene Therapeutics	N/A	9.71	9.71
INZY Inozyme Pharma	0.65	2.19	2.19
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ALLO Allogene Therapeutics	83.63%
INZY Inozyme Pharma	88.30%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
ALLO Allogene Therapeutics	13.20%
INZY Inozyme Pharma	12.18%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable

ADAP, TNXP, ALLO, and INZY Headlines

Recent News About These Companies

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's Why

July 9 at 5:39 PM | marketbeat.com

Tonix Pharma Publishes Phase 3 Trial Results

July 9 at 5:17 PM | tipranks.com

Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management

July 9 at 4:17 PM | quiverquant.comQ

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

July 9 at 4:01 PM | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's Why

July 7 at 1:14 PM | marketbeat.com

Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox

July 7 at 7:24 AM | quiverquant.comQ

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

July 7 at 7:00 AM | globenewswire.com

TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha

July 4, 2025 | seekingalpha.com

Tonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer Models

July 2, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

July 2, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's Why

July 1, 2025 | marketbeat.com

Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes

June 30, 2025 | msn.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 2.4% - Should You Buy?

June 30, 2025 | marketbeat.com

Tonix Pharmaceuticals to be added to Russell 3000, Russell 2000 indexes

June 30, 2025 | seekingalpha.com

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 30, 2025 | globenewswire.com

Tonix Pharmaceuticals Holding Corp. - TNXP | Barron's

June 29, 2025 | barrons.com

TNXP | Tonix Pharmaceuticals Holding Corp. Stock Overview (U.S.: Nasdaq) - Barron's

June 27, 2025 | barrons.com

Tonix Pharmaceuticals Holding Corp News (TNXP) - Investing.com

June 27, 2025 | investing.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.4% - Here's Why

June 27, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.7% - Still a Buy?

June 26, 2025 | marketbeat.com

Tonix Pharmaceuticals Holding Corp TNXP Company Vitals - U.S. News

June 26, 2025 | money.usnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
The Apple Comeback Will Be Better Than the Setback
By Gabriel Osorio-Mazilli | July 4, 2025
View The Apple Comeback Will Be Better Than the Setback
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
By Chris Markoch | June 24, 2025
View HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

ADAP, TNXP, ALLO, and INZY Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.28 +0.02 (+9.01%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$0.28 +0.00 (+1.52%)

As of 04:31 AM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Allogene Therapeutics NASDAQ:ALLO

$1.21 +0.01 (+0.83%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.02 (+1.24%)

As of 04:59 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Tonix Pharmaceuticals NASDAQ:TNXP

$38.36 +2.80 (+7.87%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$39.02 +0.66 (+1.71%)

As of 04:55 AM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time